SciSparc Ltd
Research SciSparc Ltd (SPRC) on Bullrun: market cap USD 3.83M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSPRC
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.83M
- Financial periodQ4 2025
- RevenueUSD 856.00K
- Net income-USD 12.18M
- Free cash flow-USD 4.14M
- Gross margin73.7%
Valuation Snapshot
latest market cap is USD 3.83M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | USD 1.31M | -USD 6.28M | -USD 5.10M | 38.7% | -22.65 | USD 1.54M | USD 46.00K | USD 8.15M |
| FY2023 | USD 2.88M | -USD 5.12M | -USD 5.89M | 76.3% | -263.84 | USD 2.08M | USD 76.00K | USD 7.61M |
| FY2022 | USD 1.35M | -USD 2.59M | -USD 12.79M | 76.1% | -309.38 | USD 3.57M | USD 27.00K | USD 6.45M |
| FY2021 | USD 0 | -USD 5.79M | -USD 5.10M | n/a | -1545.18 | USD 6.88M | USD 63.00K | USD 8.14M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.83M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.47M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.90M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.58M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.60M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 18.37M | n/a | n/a | n/a |
About SciSparc Ltd
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is SciSparc Ltd's market cap?
SciSparc Ltd's market capitalization is USD 3.83M.
What does SciSparc Ltd do?
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form.